Non-peptidic inhibitors of human chymase. Synthesis, structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1,6-dihydropyrimidine-containing trifluoromethyl ketones
F. Akahoshi et al., Non-peptidic inhibitors of human chymase. Synthesis, structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1,6-dihydropyrimidine-containing trifluoromethyl ketones, BIO MED CH, 9(2), 2001, pp. 301-315
Chymase possesses a wide variety of actions, including promotion of angiote
nsin II production and histamine release from mast cells. However, due to a
lack of effective inhibitors featuring both high inhibitory activity and h
igh metabolic stability, the pathophysiological role of chymase has not bee
n fully elucidated. We designed non-peptidic inhibitors based on the predic
ted binding mode of the peptidic chymase inhibitor Val-Pro-Phe-CF3 and demo
nstrated that the Val-Pro unit is replaceable with a (5-amino-6-oxo-2-pheny
l-1,6-dihydro-1-pyrimidinyl)acetyl moiety. Structure-activity relationship
studies revealed that phenyl substitution at the 2-position of the pyrimidi
none ring is indispensable for high activity. The most potent compound 1h (
K-i = 0.0506 muM) is superior in potency to the parent peptidic inhibitor V
al-Pro-Phe-CF3 and has good selectivity for chymase over other proteases. T
he related analogue 1e was orally absorbed and maintained high plasma level
s for at least 2 h. These results suggest that the derivatives reported her
e could be developed as agents for treatment of chymase-induced disease. (C
) 2001 Elsevier Science Ltd. All rights reserved.